ME02534B - Modulatori x receptora iz jetre - Google Patents
Modulatori x receptora iz jetreInfo
- Publication number
- ME02534B ME02534B MEP-2016-211A MEP2016211A ME02534B ME 02534 B ME02534 B ME 02534B ME P2016211 A MEP2016211 A ME P2016211A ME 02534 B ME02534 B ME 02534B
- Authority
- ME
- Montenegro
- Prior art keywords
- alkyl
- nrc
- haloalkyl
- compound
- halogen
- Prior art date
Links
- 102000004311 liver X receptors Human genes 0.000 title claims 2
- 108090000865 liver X receptors Proteins 0.000 title claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 229910003827 NRaRb Inorganic materials 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 4
- -1 haloaicoxy Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000037373 wrinkle formation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612051P | 2012-03-16 | 2012-03-16 | |
| PCT/US2013/031242 WO2013138565A1 (en) | 2012-03-16 | 2013-03-14 | Liver x receptor modulators |
| EP13712102.6A EP2825541B1 (en) | 2012-03-16 | 2013-03-14 | Liver x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02534B true ME02534B (me) | 2017-02-20 |
Family
ID=47997957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-211A ME02534B (me) | 2012-03-16 | 2013-03-14 | Modulatori x receptora iz jetre |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9006244B2 (https=) |
| EP (1) | EP2825541B1 (https=) |
| JP (3) | JP6114814B2 (https=) |
| KR (1) | KR102069912B1 (https=) |
| CN (1) | CN104203951B (https=) |
| AU (1) | AU2013232066B2 (https=) |
| CA (1) | CA2866218C (https=) |
| CY (1) | CY1118318T1 (https=) |
| DK (1) | DK2825541T3 (https=) |
| EA (1) | EA026907B1 (https=) |
| ES (1) | ES2598653T3 (https=) |
| HR (1) | HRP20161196T1 (https=) |
| HU (1) | HUE029402T2 (https=) |
| IL (1) | IL234265B (https=) |
| IN (1) | IN2014DN07636A (https=) |
| LT (1) | LT2825541T (https=) |
| ME (1) | ME02534B (https=) |
| MX (1) | MX354818B (https=) |
| NZ (1) | NZ629122A (https=) |
| PL (1) | PL2825541T3 (https=) |
| PT (1) | PT2825541T (https=) |
| RS (1) | RS55166B1 (https=) |
| SG (1) | SG11201405328SA (https=) |
| SI (1) | SI2825541T1 (https=) |
| SM (1) | SMT201600374B (https=) |
| WO (1) | WO2013138565A1 (https=) |
| ZA (1) | ZA201406326B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2607113T3 (es) * | 2012-03-16 | 2017-03-29 | Vitae Pharmaceuticals, Inc. | Moduladores de los receptores X del hígado |
| SI2825541T1 (sl) * | 2012-03-16 | 2016-10-28 | Vitae Pharmaceuticals, Inc. | Modulatorji jetrnega receptorja X |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| WO2015195922A1 (en) * | 2014-06-19 | 2015-12-23 | Vitae Pharmaceuticals, Inc. | Compounds for use in treating acute coronary syndrome and related conditions |
| EA031480B1 (ru) * | 2014-08-07 | 2019-01-31 | Вайтаи Фармасьютиклз, Инк. | Модуляторы x-рецепторов печени |
| WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| CN105017262B (zh) * | 2015-07-07 | 2017-05-03 | 广东也乐新材料制造有限公司 | 一种醛基取代多环杂芳烃化合物的合成方法 |
| CN105288658B (zh) * | 2015-10-30 | 2018-08-28 | 中国人民解放军第三军医大学 | miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用 |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748247A (en) | 1986-10-21 | 1988-05-31 | American Home Products Corporation | 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists |
| EP0511993A1 (en) | 1990-01-22 | 1992-11-11 | E.I. Du Pont De Nemours And Company | Herbicidal sulfonylureas |
| EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| WO1996012721A1 (en) | 1994-10-20 | 1996-05-02 | American Home Products Corporation | Indole derivatives useful as serotonergic agents |
| EP0912513A1 (en) | 1996-06-28 | 1999-05-06 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| EP0912182A4 (en) | 1996-06-28 | 1999-12-29 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTIC PRODRUGS |
| US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| EP0912175A4 (en) | 1996-06-28 | 1999-09-08 | Merck & Co Inc | FIBRINOGENIC RECEPTOR ANTAGONISTS |
| US6177440B1 (en) | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
| FR2761070B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| FR2761073B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| DE19802235A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Mit tricyclischen Indolen substituierte Oxazolidinone |
| IL129484A0 (en) | 1998-04-17 | 2000-02-29 | Lilly Co Eli | Substituted tricyclics |
| BR0010308A (pt) | 1999-05-06 | 2002-01-08 | Neurogen Corp | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada |
| US7037916B2 (en) | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| IT1313593B1 (it) | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo. |
| WO2001030331A2 (en) | 1999-10-22 | 2001-05-03 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
| WO2001049288A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co. | Novel compounds and compositions as protease inhibitors |
| MXPA03000906A (es) | 2000-07-31 | 2005-02-24 | Hoffmann La Roche | Derivados de piperazina. |
| HUP0303316A2 (hu) | 2000-12-20 | 2004-01-28 | Bristol-Myers Squibb Pharma Company | Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| FR2829766A1 (fr) | 2001-09-14 | 2003-03-21 | Lipha | Derives d'oxamates comportant un heterocycle azote diversement substitue |
| BR0215288A (pt) | 2001-12-21 | 2004-12-21 | King Phamaceuticals Res & Dev | Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| DE10320780A1 (de) | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
| ES2564804T3 (es) | 2004-02-12 | 2016-03-29 | Mitsubishi Tanabe Pharma Corporation | Compuesto de indazol y uso farmacéutico del mismo |
| JP2007532506A (ja) | 2004-04-08 | 2007-11-15 | ノバルティス アクチエンゲゼルシャフト | 自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤 |
| RU2266906C1 (ru) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| WO2005113526A2 (en) | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
| WO2006063709A1 (en) * | 2004-12-15 | 2006-06-22 | F.Hoffmann-La Roche Ag | Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease |
| CA2593266A1 (en) | 2005-01-03 | 2006-07-13 | Universita Degli Studi Di Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| MX2008000585A (es) | 2005-07-14 | 2008-03-14 | Hoffmann La Roche | Derivados de indol-3-il-espiro-piperidina como antagonistas del receptor v1a. |
| EP1926724A1 (en) | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| JP2007137810A (ja) * | 2005-11-17 | 2007-06-07 | Sankyo Co Ltd | インドール化合物を含有する医薬 |
| JP2009518351A (ja) | 2005-12-09 | 2009-05-07 | エフ．ホフマン−ラ ロシュ アーゲー | 肥満症の処置に有用な三環性アミド誘導体 |
| US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| FR2897061B1 (fr) | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| CA2683557C (en) | 2007-04-09 | 2016-10-18 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP2010531364A (ja) | 2007-06-25 | 2010-09-24 | ニューロジェン・コーポレーション | ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体 |
| EP2205085A1 (en) | 2007-09-25 | 2010-07-14 | Merck Sharp & Dohme Corp. | 2-aryl or heteroaryl indole derivatives |
| CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| CN101952293A (zh) * | 2007-12-21 | 2011-01-19 | 惠氏有限责任公司 | 吡唑并[1,5-a]嘧啶化合物 |
| TW200936591A (en) | 2008-01-22 | 2009-09-01 | Takeda Pharmaceutical | Tricyclic compounds and use thereof |
| WO2009097515A2 (en) | 2008-01-30 | 2009-08-06 | Wyeth | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| EP2254886B1 (en) | 2008-03-28 | 2016-05-25 | Nerviano Medical Sciences S.r.l. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| TW201031665A (en) | 2009-02-04 | 2010-09-01 | Gruenenthal Gmbh | Substituted indole-compound |
| MX2011012993A (es) | 2009-06-08 | 2011-12-16 | Gruenenthal Gmbh | Bencimidazoles, benzotiazoles y benzoxazoles, sustituidos. |
| WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| MX2012002898A (es) | 2009-09-11 | 2012-04-02 | Sunovion Pharmaceuticals Inc | Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos. |
| US9073926B2 (en) | 2009-12-07 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| WO2011109237A2 (en) | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
| US8654867B2 (en) * | 2011-12-07 | 2014-02-18 | Texas Instruments Incorporated | Transformer power combiner with filter response |
| ES2607113T3 (es) * | 2012-03-16 | 2017-03-29 | Vitae Pharmaceuticals, Inc. | Moduladores de los receptores X del hígado |
| SI2825541T1 (sl) * | 2012-03-16 | 2016-10-28 | Vitae Pharmaceuticals, Inc. | Modulatorji jetrnega receptorja X |
-
2013
- 2013-03-14 SI SI201330303A patent/SI2825541T1/sl unknown
- 2013-03-14 SG SG11201405328SA patent/SG11201405328SA/en unknown
- 2013-03-14 DK DK13712102.6T patent/DK2825541T3/en active
- 2013-03-14 MX MX2014011103A patent/MX354818B/es active IP Right Grant
- 2013-03-14 JP JP2015500602A patent/JP6114814B2/ja not_active Expired - Fee Related
- 2013-03-14 HU HUE13712102A patent/HUE029402T2/en unknown
- 2013-03-14 HR HRP20161196TT patent/HRP20161196T1/hr unknown
- 2013-03-14 RS RS20160785A patent/RS55166B1/sr unknown
- 2013-03-14 ES ES13712102.6T patent/ES2598653T3/es active Active
- 2013-03-14 LT LTEP13712102.6T patent/LT2825541T/lt unknown
- 2013-03-14 KR KR1020147028754A patent/KR102069912B1/ko not_active Expired - Fee Related
- 2013-03-14 PT PT137121026T patent/PT2825541T/pt unknown
- 2013-03-14 EP EP13712102.6A patent/EP2825541B1/en active Active
- 2013-03-14 NZ NZ629122A patent/NZ629122A/en not_active IP Right Cessation
- 2013-03-14 IN IN7636DEN2014 patent/IN2014DN07636A/en unknown
- 2013-03-14 CA CA2866218A patent/CA2866218C/en not_active Expired - Fee Related
- 2013-03-14 US US14/385,688 patent/US9006244B2/en active Active
- 2013-03-14 ME MEP-2016-211A patent/ME02534B/me unknown
- 2013-03-14 WO PCT/US2013/031242 patent/WO2013138565A1/en not_active Ceased
- 2013-03-14 EA EA201491609A patent/EA026907B1/ru unknown
- 2013-03-14 CN CN201380014354.5A patent/CN104203951B/zh not_active Expired - Fee Related
- 2013-03-14 PL PL13712102.6T patent/PL2825541T3/pl unknown
- 2013-03-14 AU AU2013232066A patent/AU2013232066B2/en not_active Ceased
-
2014
- 2014-08-24 IL IL234265A patent/IL234265B/en active IP Right Grant
- 2014-08-27 ZA ZA201406326A patent/ZA201406326B/en unknown
- 2014-11-19 US US14/547,804 patent/US9006245B2/en active Active
-
2015
- 2015-03-13 US US14/657,179 patent/US9388190B2/en active Active
-
2016
- 2016-06-15 US US15/182,749 patent/US9814715B2/en active Active
- 2016-09-22 CY CY20161100948T patent/CY1118318T1/el unknown
- 2016-10-14 SM SM201600374T patent/SMT201600374B/it unknown
-
2017
- 2017-03-14 JP JP2017048432A patent/JP2017128588A/ja active Pending
-
2018
- 2018-09-14 JP JP2018172260A patent/JP2019023196A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02534B (me) | Modulatori x receptora iz jetre | |
| ME02660B (me) | Modulator! jetrenog x receptora | |
| JP2015510892A5 (https=) | ||
| JP2015514061A5 (https=) | ||
| ME02685B (me) | Kristalni oblik pemirolasta | |
| AR122395A2 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| ES2529226T3 (es) | Nuevos componentes que se unen a FXR (NR1H4) y modulan su actividad | |
| ME01982B (me) | 2-anilinobenzimidazol-6-karboksamidi kao anti-inflamatorni agensi | |
| PE20160679A1 (es) | Inhibidores de pirimidina del fgfr4 | |
| ME02175B (me) | L-prolin i ko-kristali limunske kiseline od (2s, 3r, 4r, 5s, 6r)-2-(3- ((5- (4- fluorofenil) tiofen-2-il) metil)-4-metilfenil)-6- (hidroksimetil)tetrahidr0- 2h-piran- 3,4,s-triola | |
| HRP20230162T1 (hr) | Heteroarilni inhibitori enzima pde4 | |
| AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| BR112014029957A2 (pt) | processos para produzir determinados 2-(piridina-3-il)tiazóis | |
| AR091246A1 (es) | Procesos para producir 2-(piridin-3-il)tiazoles | |
| ME02892B (me) | Hemijska jedinjenja | |
| MA45397A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| EP2758482A4 (en) | DEVELOPMENT OF DEHNVISCOSITY FOR REDUCED SPRAYING FOR SPRAYING APPLICATIONS WITH DILUTED CONCENTRATE | |
| JP2015527394A5 (https=) | ||
| MA42488A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| EP2743283A4 (en) | NOVEL CYANIC ACID ESTER COMPOUND, PROCESS FOR THE PRODUCTION THEREOF, CURABLE RESIN COMPOSITION WITH THE NOVEL CYANIC ACID ESTER COMPOUND AND HARDENING PRODUCT FROM THE HARDENED RESIN COMPOSITION | |
| AR110155A2 (es) | ALCOHOLES TRIFLUOROMETÍLICOS COMO MODULADORES DE RORgT | |
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| WO2014036502A8 (en) | Tetracycline compounds | |
| HRP20180176T1 (hr) | Spojevi korisni u sintezi spojeva benzamida | |
| BR112014030126A2 (pt) | processos para produzir certos 2-(piridino-3-il)tiazóis |